Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Non-Current Debt (2022 - 2025)

Historic Non-Current Debt for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $92.3 million.

  • BioXcel Therapeutics' Non-Current Debt fell 1162.2% to $92.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.3 million, marking a year-over-year decrease of 1162.2%. This contributed to the annual value of $102.5 million for FY2024, which is 189.86% up from last year.
  • Latest data reveals that BioXcel Therapeutics reported Non-Current Debt of $92.3 million as of Q3 2025, which was down 1162.2% from $97.5 million recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Non-Current Debt peaked at $104.4 million during Q3 2024, and registered a low of $61.1 million during Q2 2022.
  • Moreover, its 4-year median value for Non-Current Debt was $98.3 million (2023), whereas its average is $95.6 million.
  • Per our database at Business Quant, BioXcel Therapeutics' Non-Current Debt skyrocketed by 5856.9% in 2023 and then tumbled by 1162.2% in 2025.
  • Over the past 4 years, BioXcel Therapeutics' Non-Current Debt (Quarter) stood at $93.1 million in 2022, then rose by 8.11% to $100.6 million in 2023, then rose by 1.9% to $102.5 million in 2024, then dropped by 9.96% to $92.3 million in 2025.
  • Its Non-Current Debt stands at $92.3 million for Q3 2025, versus $97.5 million for Q2 2025 and $99.9 million for Q1 2025.